Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$0.44 - $1.77 $113,941 - $458,353
-258,957 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$1.23 - $2.07 $47,957 - $80,709
-38,990 Reduced 13.09%
258,957 $412,000
Q4 2021

Feb 14, 2022

SELL
$1.75 - $3.03 $134,370 - $232,652
-76,783 Reduced 20.49%
297,947 $542,000
Q3 2021

Nov 15, 2021

SELL
$2.41 - $3.33 $1.37 Million - $1.9 Million
-569,901 Reduced 60.33%
374,730 $1.05 Million
Q2 2021

Aug 16, 2021

SELL
$2.24 - $3.9 $602,356 - $1.05 Million
-268,909 Reduced 22.16%
944,631 $2.87 Million
Q1 2021

May 14, 2021

SELL
$3.19 - $5.4 $2.28 Million - $3.85 Million
-713,359 Reduced 37.02%
1,213,540 $4.16 Million
Q4 2020

Feb 16, 2021

SELL
$3.06 - $4.17 $446,288 - $608,177
-145,846 Reduced 7.04%
1,926,899 $5.99 Million
Q2 2020

Aug 14, 2020

BUY
$3.22 - $6.08 $2.48 Million - $4.68 Million
769,093 Added 59.0%
2,072,745 $9.91 Million
Q1 2020

May 14, 2020

BUY
$3.3 - $6.84 $1.4 Million - $2.9 Million
424,452 Added 48.28%
1,303,652 $4.51 Million
Q2 2019

Aug 14, 2019

BUY
$5.68 - $8.68 $479,954 - $733,451
84,499 Added 10.63%
879,200 $6.56 Million
Q1 2019

May 15, 2019

SELL
$7.27 - $9.07 $288,619 - $360,079
-39,700 Reduced 4.76%
794,701 $6.49 Million
Q4 2018

Feb 14, 2019

SELL
$6.59 - $14.47 $28,159 - $61,830
-4,273 Reduced 0.51%
834,401 $5.7 Million
Q3 2018

Nov 14, 2018

BUY
$10.55 - $15.28 $1.03 Million - $1.49 Million
97,566 Added 13.16%
838,674 $11.4 Million
Q2 2018

Aug 14, 2018

BUY
$5.04 - $17.96 $2.18 Million - $7.77 Million
432,480 Added 140.13%
741,108 $8.82 Million
Q1 2018

May 15, 2018

SELL
$5.12 - $11.77 $467,824 - $1.08 Million
-91,372 Reduced 22.84%
308,628 $1.72 Million
Q4 2017

Feb 14, 2018

BUY
$6.78 - $9.32 $2.71 Million - $3.73 Million
400,000
400,000 $3.66 Million

About Galmed Pharmaceuticals Ltd.


  • Ticker GLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,088,400
  • Market Cap $72M
  • Description
  • Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or t...
More about GLMD
Track This Portfolio

Track Nantahala Capital Management, LLC Portfolio

Follow Nantahala Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nantahala Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nantahala Capital Management, LLC with notifications on news.